Posts

Posted on

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

Innovative product line is purpose-built to streamline the manufacture of allogeneic cell therapies. Available exclusively from Teknova starting today.

HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx’s PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, while Pluristyx is a leading provider of induced Pluripotent Stem Cells (iPSCs), including immune evading and safety-switch enabled iPSCs, and other innovative technologies designed to shorten the development lifecycle of tomorrow’s cell therapies.

As previously announced, Teknova and Pluristyx are collaborating to produce and commercialize the PluriFreeze product line, with Teknova becoming the exclusive manufacturer and distributor in the United States and Canada. The PluriFreeze cryopreservation system is entirely synthetic and animal-origin-free, and includes a unique protective wash paired with a proven freezing medium to streamline development and commercialization of next generation allogeneic cell therapies. PluriFreeze Base is a cellular wash that mimics intracellular space and provides end-to-end metabolic support. PluriFreeze PF10 is a low viscosity freezing medium with 10% dimethyl sulfoxide (DMSO) that simplifies scale-up and process automation.

“Making solutions possible for our customers is our focus at Teknova,” said Jennifer Henry, Teknova’s Senior Vice President of Marketing, “and through our collaboration with Pluristyx, we’re now able to help developers quickly and confidently scale with PluriFreeze. The unique pairing of PluriFreeze Base and PF10 provides an ideal environment for cells to remain viable and functional throughout the cell product lifecycle, streamlining manufacturing from research through commercialization.”

“Through our development of iPSCs, we recognized how important it is to choose the right biopreservation reagents to protect cells during both hypothermic storage and cryopreservation, and at multiple holding points across the workflow,” explained Dr. Jason Carstens, Chief Operating Officer and Co-Founder of Pluristyx. “Our proprietary PluriFreeze cryopreservation system can be introduced early in the workflow, enabling cell therapy developers to better control and optimize biopreservation conditions and outcomes. And now, with wider access to PluriFreeze thanks to our collaboration with Teknova, customers can choose high-quality RUO and GMP-grade versions of PluriFreeze Base and PF10, or tailor them further to support specific cell types.”

The PluriFreeze cryopreservation system is available for purchase today via phone, email, or online. Research-grade products are priced starting at $240 per 100 mL bottle of PluriFreeze Base and $260 per 100 mL bottle of PluriFreeze PF10. Customers can purchase both products in GMP-grade at prices quoted on request. Teknova can also produce custom formulations and configurations for use with specific cell types. Free product samples are available through Friday, March 21, 2025, by registering here.

For more information about the PluriFreeze cryopreservation system or to purchase PluriFreeze Base or PF10 online, visit http://www.teknova.com/pluristyx.

ABOUT TEKNOVA

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in molecular diagnostics, synthetic biology, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.

ABOUT PLURISTYX

Pluristyx is a privately held biotechnology company offering a wide range of products and services to support the development and manufacture of cell and gene therapies, including iPSC lines, proprietary genetic engineering technologies, differentiation services, iPSC culture kits, and contract development services. Pluristyx is committed to delivering highest quality products and services to accelerate clinical translation of life-changing cell therapies.

CONTACTS

Investor Contact (Teknova)

Matt Lowell 
Chief Financial Officer 
[email protected]
+1 831-637-1100 

Media Contact
 
(Teknova)

Jennifer Henry
Senior Vice President, Marketing 
[email protected]
+1 831-313-1259 

Media Contact
 
(Pluristyx)

Steve Geelhood
Senior Director, Commercial Operations
[email protected]
+1 888-588-9935

This press release was published by a CLEAR® Verified individual.



Posted on

SHAREHOLDER ALERT: Kaskela Law LLC Announces Class Action Lawsuit Against Origin Materials, Inc. (ORGN) and Encourages Long-Term Origin Investors to Contact the Firm

PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Origin Materials, Inc. (NASDAQ: ORGN) (“Origin”) on behalf of certain investors who purchased shares of the company’s stock between February 23, 2023 and August 9, 2023 (the “Class Period”).


Click here to receive additional information:



https://kaskelalaw.com/case/origin-materials/

According to the complaint, on February 17, 2021, Origin announced that it was undertaking a capital project to build the company’s largest and first commercial-scale plant, called Origin 2, which would produce paraxylene (PX). The defendants then represented that Origin 2’s construction would begin by mid-2023 and would be operational in mid-2025, and that the plant was expected to supply most of the Company’s products from 2025-2027.

However, the complaint charges defendants with actively misleading investors during the Class Period by failing to disclose that (i) Origin would not be able to meet its previously announced timeline for the construction of the Origin 2 plant; (ii) demand for PX had dropped such that it would not be the production focus of Origin 2; (iii) Origin could not construct Origin 2 at its previously disclosed cost; (iv) Origin could not construct Origin 2 at the scale it had previously identified; and (v) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and lacked a reasonable basis.

As detailed in the complaint, on August 9, 2023, Origin shocked the market when it reported its financial results for second quarter of 2023 and disclosed that Origin 2 was not progressing towards a mid-2025 start-up as previously represented, and that the plant would be smaller in scale than represented, cost more, and no longer produce its target product, PX. Following this disclosure, shares of the company’s stock fell $2.88 per share, or over 66% in value, to close at $1.45 per share on August 10, 2023.

The investigation seeks to determine – on behalf of Origin’s current shareholders – whether the members of Origin’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct and misstatements.


Current Origin stockholders


who purchased or acquired shares of the company’s stock



prior to February 23, 2023



are encouraged to contact


Kaskela Law LLC


(D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) to receive additional information about their legal rights and options at (484) 229 – 0750,


or by clicking on the following link (or by copying and pasting the link into your browser):



https://kaskelalaw.com/case/origin-materials/

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.

CONTACT:

KASKELA LAW LLC

D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 – 0750
www.kaskelalaw.com



Posted on

AgEagle Aerial Systems Announces Key Sales Leadership Appointments to Fortify its Strategic Growth Plan

Over 40 years of combined drone industry expertise to support robust global sales initiatives

WICHITA, Kan., March 19, 2025 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (NYSE: UAVS) a leading provider of best-in-class unmanned aerial systems (UAS), sensors and software solutions for customers worldwide in the commercial and government verticals, announces the appointment of Steve Mathias as Vice President of Global Sales and Business Development and Erik de Badts as Global Head of MicaSense Sales.

AgEagle CEO Bill Irby commented, “As we execute a multi-faceted strategic growth plan focused on expanding our global footprint, the addition of both Steve and Erik’s impressive pedigrees will drive innovation, foster collaboration, and ensure that we remain agile in an evolving UAS marketplace. Steve brings multi-decade expertise in military and commercial aviation, both crewed and uncrewed, while Erik is a true subject matter expert in multi-spectral sensing. We are confident their leadership will help strengthen key partner relationships, unlock new opportunities, and accelerate revenue growth.”

Steve Mathias is an aerospace business executive with over 30 years of senior leadership experience in both the military and aerospace industry. Prior to joining AgEagle, he served as Senior Vice President of Strategy and Growth at GKN Aerospace Defense, a leading global technology company specializing in advanced aerostructures and engine systems. Before his role at GKN Aerospace, Mr. Mathias was Vice President of Global Sales and Strategy at Bell Helicopter, where he led all domestic and international vertical lift defense sales, including both crewed and uncrewed systems. His background as a U.S. Army Officer includes significant special operations and conventional aviation experience with both manned and unmanned systems. In his final Army assignment, Steve served as the Deputy Chief of Staff G-8 for the U.S. Army Special Operations Command, overseeing the requirements and Program Objective Memorandum (POM) processes for over 200 Army and Special Operations air and land programs.

Erik de Badts will be re-joining AgEagle taking a leadership role in our worldwide camera sales. Erik is a remote sensing expert and served previously in a camera sales leadership role for MicaSense and AgEagle for eight years. He is a geospatial and drone industry professional with over 20 years of experience in international business development, remote sensing, image processing and drone manufacturing.

About AgEagle Aerial Systems Inc.

Through its three centers of excellence, AgEagle is actively engaged in designing and delivering best-in-class flight hardware, sensors and software that solve important problems for its customers. Founded in 2010, AgEagle was originally formed to pioneer proprietary, professional-grade, fixed-winged drones and aerial imagery-based data collection and analytics solutions for the agriculture industry. Today, AgEagle is a leading provider of full stack UAS, sensors and software solutions for customers worldwide in the energy, construction, agriculture, and government verticals. For additional information, please visit our website at www.ageagle.com.

Forward-Looking Statements 

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on AgEagle’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future purchase orders relating to AgEagle’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of AgEagle in general, see the risk disclosures in the Annual Report on Form 10-K of AgEagle for the year ended December 31, 2023, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by AgEagle. All such forward-looking statements speak only as of the date they are made, and AgEagle undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.

AgEagle Aerial Systems Contacts

Investor Relations:

Email: [email protected]
Media:
Email: [email protected]



Posted on

Oxbridge / SurancePlus Announces Partnership with Plume, Expanding Access to Millions of Potential Investors

GRAND CAYMAN, Cayman Islands, March 19, 2025 (GLOBE NEWSWIRE) —

Oxbridge Re Holdings Limited

(Nasdaq:

OXBR

) (“Oxbridge Re”), through its subsidiary SurancePlus, is engaged in the tokenization of Real-World Assets (“RWAs”), initially with tokenized reinsurance securities, today announced SurancePlus’ partnership with Plume, a leading blockchain optimized for Real-World Asset Finance (RWAfi). This collaboration aims to significantly expand the distribution of SurancePlus’ 2025-2026 tokenized reinsurance securities – EtaCat Re and ZetaCat Re – which target annual returns of 20% and 42%, respectively.

Plume provides an extensive ecosystem for distributing tokenized assets, making this collaboration a significant step toward increasing investor participation in high-yield, RWA backed securities. Plume provides seamless RWA distribution to over 18 million unique addresses, facilitating more than 280 million transactions, with $4.5 billion in committed assets on its platform. This underscores its influence in the tokenized finance space, presenting a valuable distribution opportunity for SurancePlus’ securities.

Jay Madhu
, CEO of Oxbridge, commented, “Announcing this partnership at Digital Assets Summit 2025 aligns perfectly with our vision of democratizing access to institutional-grade reinsurance investments. Plume’s ecosystem presents a strong opportunity to expand the distribution of our 2025 reinsurance securities and connect with a broader audience of investors seeking high yield opportunities that are uncorrelated to the capital markets. SurancePlus’ parent company, Nasdaq-listed Oxbridge, brings critical elements of compliance and transparency, bridging the gap between blockchain/RWAs and the SEC.”

Chris Yin
, CEO & Co-Founder of Plume, commented: “Plume is committed to bridging traditional finance and blockchain by offering access to yield-bearing real world assets. Working with SurancePlus aligns perfectly with our mission. Their balanced yield offering, EtaCat Re, and their high-yield offering, ZetaCat Re, represent exactly the type of opportunities our investors are looking for.”

Why This Collaboration Matters

  • Expanded Investor Reach:
    Plume’s extensive ecosystem and DeFi infrastructure provide immediate access to millions of active users, significantly broadening the potential investor base for EtaCat Re and ZetaCat Re.
  • Efficient & Scalable Distribution:
    Plume’s full-stack, vertically integrated technology ensures seamless issuance, trading, and integration of RWAs, enhancing the liquidity and accessibility of SurancePlus’ tokenized securities.
  • Alignment with Institutional & Retail Demand:
    Plume specializes in connecting investors with yield-generating RWAs, ensuring that SurancePlus’ offerings reach the right audience – those seeking stable, transparent, and high-yield investment opportunities.

By integrating with Plume, SurancePlus builds on its position as a leader in tokenized reinsurance securities, reinforcing its commitment to providing investors with access to fully collateralized, high-return digital securities backed by real-world reinsurance contracts.



Disclaimer



: This press release does not constitute an offer to sell nor a solicitation of an offer to buy the ZetaCat Re or EtaCat Re tokenenized reinsurance securities (the “Securities”). The Securities are not required to be, and have not been, registered under the United States Securities Act of 1933, as amended, in reliance on the exemptions provided by Regulation S and SEC Rule 506(c) thereunder. Offers and sales of the Securities are made only by, and pursuant to, the terms set forth in the Confidential Private Placement Memorandum relating to the Securities. The offering of the Securities is not being made to persons in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky, or other laws of such jurisdiction.

About Oxbridge Re Holdings Limited

Oxbridge Re Holdings Limited (NASDAQ: OXBR, OXBRW) (“Oxbridge”) is headquartered in the Cayman Islands. The company offers tokenized Real-World Assets (“RWAs”) as tokenized reinsurance securities and reinsurance business solutions to property and casualty insurers, through its wholly owned subsidiaries SurancePlus Inc., Oxbridge Re NS, and Oxbridge Reinsurance Limited.

Insurance businesses in the Gulf Coast region of the United States purchase property and casualty reinsurance through our licensed reinsurers Oxbridge Reinsurance Limited and Oxbridge Re NS.

Our Web3-focused subsidiary, SurancePlus Inc. (“SurancePlus”), has developed the first “on chain” reinsurance RWA of its kind to be sponsored by a subsidiary of a publicly traded company. By digitizing interests in reinsurance contracts as on-chain RWAs, SurancePlus has democratized the availability of reinsurance as an alternative investment to both U.S. and non U.S. investors.

Company Contact:
Oxbridge Re Holdings Limited
Jay Madhu, CEO
+1 345-749-7570
[email protected]

About Plume

Plume is the first full-stack L1 RWA chain purpose-built for Real World Asset Finance (RWAfi), enabling the integration and adoption of real world assets through its ecosystem. With 180+ protocols building on the network and a $25M RWAfi Ecosystem Fund for early-stage projects, Plume offers a composable, EVM-compatible environment for onboarding and managing diverse real world assets. Coupled with an end-to-end tokenization engine and a network of financial infrastructure partners, Plume enables seamless DeFi integration for RWAs so anyone can tokenize real world assets, distribute them globally, and make them useful for blockchain native users.

Learn More:
https://plumenetwork.xyz and https://x.com/plumenetwork

Company Contact:
[email protected]

Forward-Looking Statements

This press release may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are not guarantees of future results and conditions but rather are subject to various risks and uncertainties. A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially from such forward-looking statements is included in the section entitled “Risk Factors” contained in our Form 10-K filed with the Securities and Exchange Commission (“SEC”) on 26th March 2024 and in our other filings with the SEC. The occurrence of any of these risks and uncertainties could have a material adverse effect on the Company’s business, financial condition and results of operations. Any forward-looking statements made in this press release speak only as of the date of this press release and, except as required by law, the Company undertakes no obligation to update any forward looking statement contained in this press release, even if the Company’s expectations or any related events, conditions or circumstances change.



Posted on

Magnite’s ClearLine Equips Cross Screen Media with the Tools to Maximize Voter Reach

Magnite’s self-service buying solution enabled Cross Screen Media to drive incremental reach during the 2024 election

WASHINGTON, March 19, 2025 (GLOBE NEWSWIRE) — Magnite (NASDAQ: MGNI), the largest independent sell-side advertising company, announced an expanded partnership with Cross Screen Media following a successful 2024 election cycle. The adoption of ClearLine, Magnite’s self-service buying solution, helped Cross Screen Media bypass middlemen, put more spend toward working media, and drive incremental voter reach.

In a 2024 statewide race, ClearLine was used in parallel with two DSPs and a linear TV schedule. Cross Screen Media’s measurement solution found that over a two-week period in October, ClearLine drove 4% incremental reach beyond the other digital and TV components, and 8% incremental reach beyond the DSPs alone.

“It’s the job of every political advertiser to identify the voters that will swing an election and ensure your message is reaching them,” said Chauncey Southworth, CEO of Cross Screen Media. “Adding ClearLine removes intermediaries, creates a more direct line between campaign ad dollars and voters, and in combination with our cross-screen measurement solution, drives incremental reach that can be the difference in an election.”

Founded in 2017, Cross Screen Media offers advertising technology built for politics, empowering agencies and their campaigns to win elections through data-driven media planning, activation, and measurement. With 40% of swing voters nationwide unreachable via linear TV, and elections often decided by fractions of a percent, direct avenues to CTV inventory are crucial to ensuring advertisers can maximize reach amongst likely voters. The fast-paced nature of politics means buyers need a responsive platform that makes it easy to adjust budgets, creatives, and targeting in an instant. Magnite’s ClearLine delivers on this by streamlining the buying process, establishing a more direct and efficient route to premium inventory, and significantly increasing spend allocated toward working media.

“The savviest political advertisers are always seeking innovative, highly efficient, and measurable ways to connect with voters,” said Erik Brydges, Head of Political Demand at Magnite. “ClearLine helps Cross Screen Media and their agency customers accomplish this goal, and represents the future of how we believe CTV will be transacted. As CTV’s share of spend continues to grow, executing budgets directly within the supply side tech ecosystem provides immediate advantages to political campaigns.”

About Magnite

We’re Magnite (NASDAQ: MGNI), the world’s largest independent sell-side advertising company. Publishers use our technology to monetize their content across all screens and formats including CTV, online video, display, and audio. The world’s leading agencies and brands trust our platform to access brand-safe, high-quality ad inventory and execute billions of advertising transactions each month. Anchored in bustling New York City, sunny Los Angeles, mile high Denver, historic London, colorful Singapore, and down under in Sydney, Magnite has offices across North America, EMEA, LATAM, and APAC.

About Cross Screen Media

Cross Screen Media is a leading CTV activation managed service for political and public affairs agencies, built on a proprietary technology platform that enables advertisers to plan and measure local advertising across Connected TV and audience-driven Linear TV. We seamlessly fit into existing workflows to help agencies scale, differentiate and deliver high-impact campaigns for their clients.

Media Contact:

Megan Hughes
[email protected]



Posted on

Dynatrace Named a Leader in the 2025 GigaOm Radar Report for Cloud Observability

Dynatrace Named a Leader in the 2025 GigaOm Radar Report for Cloud Observability

Company also named an Outperformer, reflecting its ability to deliver the highest value to customers with leading AI-powered observability

WALTHAM, Mass.–(BUSINESS WIRE)–Dynatrace (NYSE: DT), the leading AI-powered observability platform, today announced it has been named a Leader and Outperformer in the 2025 GigaOm Radar Report for Cloud Observability.

This position underscores the company’s industry leadership and proven ability to help customers turn complex data into an asset by leveraging its AI-powered observability platform. GigaOm evaluated 23 solution providers based on a range of criteria, including technical capabilities, product roadmap, innovation, and ability to execute. Download a complimentary copy of the 2025 GigaOm Radar Report for Cloud Observability now.

According to GigaOm analyst Shane Archiquette, the report’s author, “The (Dynatrace) platform supports observability as code, enabling seamless integration into DevOps workflows and infrastructure as code practices. Dynatrace’s approach emphasizes stability and continuous enhancement, ensuring consistent performance and reliability for its users. It prioritizes advanced automation, detailed analytics, and a broad range of integrations across IT environments, making Dynatrace a preferred choice for enterprises requiring robust, end-to-end observability.”

“This recognition from GigaOm validates Dynatrace’s ability to drive exceptional customer value through our industry-leading AI-powered observability platform,” said Steve Tack, Chief Product Officer, Dynatrace. “Organizations are flooded with data, facing growing complexity and a constant pressure to adopt and drive revenue from AI. As they continue to leverage hyperscaler cloud platforms for faster innovation, while embracing evolving technologies like generative AI and LLMs, we remain committed to delivering the insights and visibility required to optimize and scale so they can realize the greatest possible ROI from their technology investments.”

About Dynatrace

Dynatrace is advancing observability for today’s digital businesses, helping to transform the complexity of modern digital ecosystems into powerful business assets. By leveraging AI-powered insights, Dynatrace enables organizations to analyze, automate, and innovate faster to drive their business forward. To learn more about how Dynatrace can help your business, visit www.dynatrace.com, visit our blog and follow us on LinkedIn and X @dynatrace.

Curious to see how you can simplify your cloud and maximize the impact of your digital teams? Let us show you. Sign up for a 15-day Dynatrace trial.

Investor:

Noelle Faris

VP, Investor Relations

[email protected]

Media Relations:

Dynatrace PR Team

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Data Management Security Technology Other Technology Software Artificial Intelligence

MEDIA:

Logo
Logo
Posted on

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

New human pharmacokinetic (PK) and other pre-clinical data supports use of RenovoRx’s novel Trans-Arterial Micro-Perfusion (TAMP™) therapy platform

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, is proud to announce a presentation of a new pre-clinical clinical data abstract at the upcoming Society of Surgical Oncology (SSO) 2025 Annual Meeting.

The abstract, titled “Pharmacodynamics of Intra-arterial vs. Intravenous Gemcitabine in Locally Advanced Pancreatic Cancer: Results of a Phase III Randomized Clinical Trial,” is co-authored by Dr. Ramtin Agah, RenovoRx’s Chief Medical Officer. The abstract supports RenovoRx’s proprietary Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform via additional human PK data and pre-clinical data.

TAMP is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to locoregional treatment offers the potential for increased safety, tolerance, and improved efficacy.

RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial is evaluating the Company’s novel investigational drug-device combination product candidate, (intra-arterial delivery of gemcitabine via RenovoCath) known as IAG, utilizing the TAMP drug delivery platform in patients with Locally Advanced Pancreatic Cancer (LAPC). RenovoRx currently anticipates the completion of both patient enrollment and the second interim analysis for TIGeR-PaC in mid-2025. This abstract is a sub-study of the TIGeR-PaC clinical trial. The combination product candidate (IAG), which is enabled by the FDA-cleared RenovoCath device, is currently under investigation and has not been approved for commercial sale.

SSO 2025 Abstract Details:

  • Title: Pharmacodynamics of Intra-arterial vs. Intravenous Gemcitabine in Locally Advanced Pancreatic Cancer: Results of a Phase III Randomized Clinical Trial
  • Authors: Emmanuel Zervos MD, Paula Novelli MD, Amer Zureikat MD, Michael Pishvaian MD, Kenneth Meredith MD, Hassan Hatoum MD, Reza Nazemzadeh MD, Sandeep Loria MD, Ramtin Agah MD
  • Location: ePoster P379 at Tampa Convention Center, Tampa, FL
  • Dates: March 27 – 29, 2025

About RenovoCath

Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-F-Universal-IFU.pdf.

About the TIGeR-PaC Clinical Trial

TIGeR-PaC is an ongoing Phase III randomized multi-center study evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of LAPC. RenovoRx’s first investigational drug-device combination product candidate (intra-arterial delivery of gemcitabine via RenovoCath, known as IAG) using the TAMP therapy platform enabled with the Company’s FDA-cleared RenovoCath® device for the intra-arterial administration of chemotherapy, gemcitabine.

The first interim analysis in the Phase III clinical trial was completed in March 2023, with the Data Monitoring Committee recommending a continuation of the study. The TIGeR-PaC study is investigating TAMP in LAPC. The study’s primary endpoint is an overall survival benefit with secondary endpoints including reduced side effects versus standard of care. The second interim analysis for this study will be triggered by the 52nd event (i.e., patient death), which is estimated to occur in the second quarter of 2025. The second interim data readout would follow thereafter, with the timing for such readout depending on customary factors such as time needed for analysis. RenovoRx is also aiming to complete patient enrollment in the TIGeR-PaC study in mid-2025.

About RenovoRx, Inc.

RenovoRx is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.

In addition to the RenovoCath device, RenovoRx is also evaluating our novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). IAG is being evaluated under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. The investigational IAG utilizes RenovoCath, the Company’s FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. The intra-arterial infusion of chemotherapy, gemcitabine, utilizing the RenovoCath device is currently being evaluated for the treatment of LAPC by the Center for Drug Evaluation and Research (the drug division of FDA).

IAG by the RenovoCath catheter is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides 7 years of market exclusivity upon new drug application approval by the FDA.

RenovoRx is also engaged in implementing commercialization strategies utilizing its TAMP technology and FDA-cleared RenovoCath device as stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices. Additionally, certain of these customers have already initiated repeat orders as RenovoRx works to expand the number medical institutions that have initiated the process for RenovoCath purchase orders, including several esteemed, high volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity either on its own or in tandem with a medical device commercial partner.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of the Company’s management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our pre-clinical and clinical trials and studies, including the overall timing and timing for additional interim data readouts for our ongoing TIGeR-PaC Phase III clinical trial study in LAPC, (ii) the potential of RenovoCath® or TAMP™ as standalone commercial products, our anticipated timing for revenue generation from RenovoCath sales, and our commercialization plans in general, (iii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iv) our efforts to explore commercialization strategies utilizing our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, commercial plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to significant known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our execution of our commercial strategy for RenovoCath or our TAMP technology may not lead to viable or repeating revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding, (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of TIGeR-PaC and any other preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

KCSA Strategic Communications

Valter Pinto or Jack Perkins

T:212-896-1254

[email protected]

KEYWORDS: United States North America California Florida

INDUSTRY KEYWORDS: Research Surgery FDA Clinical Trials Health Pharmaceutical General Health Science Oncology

MEDIA:

Logo
Logo
Posted on

Corporacion America Airports Reports Fourth Quarter and Full Year 2024 Results

Corporacion America Airports Reports Fourth Quarter and Full Year 2024 Results

Solid results with Adjusted EBITDA margin expansion in all geographies mitigated soft performance in Argentina

Passenger traffic in Argentina rebounded to record-highs in Dec ’24 and Jan ‘25

Cash & Cash Equivalents at $440 million with Net Debt to LTM Adjusted EBITDA of 1.1x

LUXEMBOURG–(BUSINESS WIRE)–Corporación América Airports S.A. (NYSE: CAAP), (“CAAP” or the “Company”) one of the leading private airport operators in the world, reported today its unaudited, consolidated results for the three-month period ended December 31, 2024, and audited results for the full year 2024. Financial results are expressed in millions of U.S. dollars and are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (“IASB”).

Commencing 3Q18, the Company began reporting results of its Argentinean subsidiaries applying Hyperinflation Accounting, in accordance with IFRS rule IAS 29 (“IAS 29”), as detailed in Section“Hyperinflation Accounting in Argentina” on page 23.

Fourth Quarter 2024 Highlights

  • Consolidated Revenues ex-IFRIC12 totaled $396.2 million, up 23.1% year-over-year (YoY), driven by increases of 29.0% and 17.5% in Aeronautical Revenues and Commercial Revenues, respectively. Excluding rule IAS 29, consolidated revenues ex-IFRIC12 decreased 0.6% YoY to $395.2 million.
  • Key operating metrics:

    • 1.2% decrease in passenger traffic to 20.5 million, but up 1.5% when excluding Natal.
    • 16.3% increase in cargo volume to 118.2 thousand tons.
    • 1.9% increase in aircraft movements, or 4.3% when excluding Natal.
  • Operating Income of $108.4 million, compared with $263.6 million in 4Q23 which included a $62.7 million portion of the $166.5 million EBITDA contribution from the indemnification payment received in connection with the friendly termination of the Natal airport concession agreement in Brazil.
  • Adjusted EBITDA ex-IFRIC12 decreased 49.5% to $150.8 million, from $298.8 million in the year-ago period. Excluding the impact of rule IAS 29 and the aforementioned Natal-related contribution recorded in 4Q23, Adjusted EBITDA ex-IFRIC12 decreased 6.7% to $150.5 million.
  • Adjusted EBITDA margin ex-IFRIC12 was 38.0% compared to 92.9% in 4Q23. Adjusting for both rule IAS 29 and the Natal-related impact in 4Q23, Adjusted EBITDA margin ex-IFRIC12 contracted to 38.1% from 40.5% in the prior-year quarter.
  • Strong liquidity position with Cash & Cash equivalents of $439.8 million as of December 31, 2024.
  • Net debt to LTM Adjusted EBITDA improved to 1.1x as of December 31, 2024, from 1.4x as of December 31, 2023.

Full Year 2024 Highlights

  • Consolidated Revenues ex-IFRIC12 increased 29.0% year-over-year (YoY) to $1,619.9 million, reflecting increases of 36.0% and 22.4% in Aeronautical Revenues and Commercial Revenues, respectively. Excluding rule IAS 29, consolidated revenues ex-IFRIC12 decreased 0.4% YoY to $1,534.6 million.
  • Key operating metrics:

    • 2.7% decrease in passenger traffic to 79.0 million, or 0.4% lower when excluding Natal.
    • 7.5% increase in cargo volume to 398.0 thousand tons.
    • 3.0% decrease in aircraft movements, or 1.3% lower when excluding Natal.
  • Operating Income of $447.3 million, compared to $540.6 million in 2023. Operating income in 2023 included a $62.7 million portion of the $166.5 million EBITDA contribution from the indemnification payment received in connection with the friendly termination of the Natal airport concession agreement in Brazil.
  • Adjusted EBITDA ex-IFRIC12 decreased 7.3% to $622.2 million, from $671.3 million in 2023. Excluding rule IAS 29 and the aforementioned Natal-related contribution recorded in 4Q23, Adjusted EBITDA ex-IFRIC12 decreased 8.5% to $581.5 million.
  • Adjusted EBITDA margin ex-IFRIC12 of 38.4% compared to 53.5% in 2023. Adjusting for both rule IAS 29 and the Natal contribution in 4Q23, Adjusted EBITDA margin ex-IFRIC12 contracted to 37.9% from 41.2% in 2023.
  • Strong liquidity position with Cash & Cash equivalents totaling $439.8 million as of December 31, 2024.
  • Net debt to LTM Adjusted EBITDA improved to 1.1x as of December 31, 2024, from 1.4x as of December 31, 2023.

CEO Message

Commenting on the results for the quarter Mr. Martín Eurnekian, CEO of Corporación América Airports, noted: “Our fourth-quarter results reflect, once again, the strength of our diversified portfolio, which continues to support our solid performance despite the challenges we faced in Argentina. While total passenger traffic declined slightly in the quarter, we were encouraged by a notable rebound in domestic traffic in Argentina toward year-end, culminating in record-high passenger volumes in December. This positive momentum extended into the first months of 2025. International passenger traffic in Argentina performed particularly well during the quarter, increasing by more than 11% year-over-year and driving hard-currency revenue streams. This encouraging trend, combined with solid contributions from our operations in Italy, Uruguay, and Brazil, underscores the strength of our geographically diverse portfolio.

On the financial front, consolidated 4Q24 comparisons were affected by the sharp devaluation of the Argentine peso in December 2023 and the indemnification payment received in 4Q23, in connection with Natal termination. The latter also impacted comparability in the Brazil segment. Excluding these factors, revenues declined 0.6%, in line with lower passenger volumes. By contrast, revenue per passenger improved slightly, reflecting our focus on efficiency and commercial revenue growth. Importantly, all regions except Argentina, delivered positive year-over-year Adjusted EBITDA contributions, helping mitigate softness in the Argentine market, which has already shown signs of improvement in the first two months of 2025.

We are advancing key initiatives to enhance the passenger experience and drive commercial revenue growth across our network. In Argentina, we are expanding Ezeiza Airport’s duty-free arrivals area by over 50% to 1,100 square meters. In Uruguay, we inaugurated a new state-of-the art private aviation terminal at Punta del Este Airport, and the construction of a new covered parking facility at Montevideo Airport is progressing as planned. We are also advancing development projects in Armenia and Italy and remain active in exploring opportunities that align with our long-term growth strategy.

In conclusion, we remain committed to advancing our strategic growth plans while building on the strong results achieved throughout 2024. With a solid balance sheet and a net leverage ratio of 1.1x, we are well-positioned to support our growth initiatives while remaining committed to delivering long-term value for our shareholders.”

Operating & Financial Highlights

(In millions of U.S. dollars, unless otherwise noted)

 

4Q24 as reported

4Q23 as reported

% Var as reported

IAS 29 4Q24

4Q24 ex IAS 29

4Q23 ex IAS 29

% Var ex IAS 29

Passenger Traffic (Million Passengers)

20.5

20.7

-1.2%

 

20.5

20.7

-1.2%

Revenue

461.1

365.0

26.3%

-0.6

461.6

454.6

1.5%

Aeronautical Revenues

211.6

164.0

29.0%

-1.1

212.7

209.1

1.7%

Non-Aeronautical Revenues

249.5

201.0

24.1%

0.6

248.9

245.5

1.4%

Revenue excluding construction service

396.2

321.8

23.1%

1.1

395.2

397.6

-0.6%

Operating Income / (Loss)

108.4

263.6

-58.9%

-26.3

134.7

305.1

-55.9%

Operating Margin

23.5%

72.2%

-4,869

0.0%

29.2%

67.1%

-3,793

Net (Loss) / Income Attributable to

Owners of the Parent

34.4

130.7

-73.7%

13.1

21.3

34.9

-38.9%

Basic EPS (US$)

0.21

0.81

-73.6%

0.08

0.13

0.22

-39.0%

Adjusted EBITDA

155.4

303.4

-48.8%

0.3

155.1

332.3

-53.3%

Adjusted EBITDA Margin

33.7%

83.1%

-4940

–

33.6%

73.1%

-3,948

Adjusted EBITDA Margin excluding Construction Service

38.0%

92.9%

-5481

–

38.1%

82.4%

-4,435

Net Debt to LTM Adjusted EBITDA

1.1x

1.4x

–

–

–

–

–

Net Debt to LTM Adjusted EBITDA excl.

impairment on intangible assets (1)

1.1x

1.7x

–

–

–

–

–

Note: Figures in historical dollars (excluding IAS29) are included for comparison purposes.

1) LTM Adjusted EBITDA excluding impairments of intangible assets.

Operating & Financial Highlights

(In millions of U.S. dollars, unless otherwise noted)

 

2024 as reported

2023 as reported

% Var as reported

IAS 29 2024

2024 ex

IAS 29

2023 ex

IAS 29

% Var ex IAS 29

Passenger Traffic (Million Passengers)

79.0

81.1

-2.7%

 

79.0

81.1

-2.7%

Revenue

1,843.3

1,400.0

31.7%

94.0

1,749.2

1,741.5

0.4%

Aeronautical Revenues

876.7

644.5

36.0%

47.8

828.9

803.6

3.1%

Non-Aeronautical Revenues

966.5

755.6

27.9%

46.2

920.3

937.8

-1.9%

Revenue excluding construction service

1,619.9

1,255.3

29.0%

85.3

1,534.6

1,541.0

-0.4%

Operating Income / (Loss)

447.3

540.6

-17.3%

-59.3

506.5

707.0

-28.4%

Operating Margin

24.3%

38.6%

-1,435

–

29.0%

40.6%

-1164

Net (Loss) / Income Attributable to

Owners of the Parent

282.7

239.5

18.0%

68.6

214.0

126.5

69.2%

Basic EPS (US$)

1.76

1.49

17.9%

0.43

1.33

0.79

69.0%

Adjusted EBITDA

628.7

677.7

-7.2%

40.7

588.0

808.4

-27.3%

Adjusted EBITDA Margin

34.1%

48.4%

-1,430

–

33.6%

46.4%

-1,280

Adjusted EBITDA Margin excluding

Construction Service

38.4%

53.5%

-1506

–

37.9%

52.0%

-1,414

Net Debt to LTM Adjusted EBITDA

1.1x

1.4x

–

–

–

–

–

Net Debt to LTM Adjusted EBITDA excl.

impairment on intangible assets (1)

1.1x

1.7x

–

–

–

–

–

Note: Figures in historical dollars (excluding IAS29) are included for comparison purposes.

1) LTM Adjusted EBITDA excluding impairments of intangible assets.

To obtain the full text of this earnings release and the earnings presentation, please click on the following link: http://investors.corporacionamericaairports.com/Results-Center

4Q24 EARNINGS CONFERENCE CALL

When: 09:00 a.m. Eastern Time, March 19, 2025

Who:

Mr. Martín Eurnekian, Chief Executive Officer

Mr. Jorge Arruda, Chief Financial Officer

Mr. Patricio Iñaki Esnaola, Head of Investor Relations

Dial-in:

1-800-549-8228 (North America, Toll Free); 1-289-819-1520 (Other locations); Conference ID: 69248

Webcast:

CAAP 4Q24 Earnings Conference Call

Replay:

1-888-660-6264 (North America, Toll Free); 1-289-819-1325 (Other locations); Playback Passcode: 69248 #

Use of Non-IFRS Financial Measures

This announcement includes certain references to Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted EBITDA excluding Construction Service and Adjusted EBITDA Margin excluding Construction service, as well as Net Debt:

Adjusted EBITDA is defined as income for the period before financial income, financial loss, income tax expense, depreciation and amortization.

Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by total revenues.

Adjusted EBITDA excluding Construction Service (“Adjusted EBITDA ex-IFRIC”) is defined as income for the period before construction services revenue and cost, financial income, financial loss, income tax expense, depreciation and amortization.

Adjusted EBITDA Margin excluding Construction Service (“Adjusted EBITDA Margin ex-IFRIC12”) excludes the effect of IFRIC 12 with respect to the construction or improvements to assets under the concession and is calculated by dividing Adjusted EBITDA excluding Construction Service revenue and cost, by total revenues less Construction service revenue.

Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted EBITDA excluding Construction Service and Adjusted EBITDA Margin excluding Construction Service are not measures recognized under IFRS and should not be considered as an alternative to, or more meaningful than, consolidated net income for the year as determined in accordance with IFRS or as indicators of our operating performance from continuing operations. Accordingly, readers are cautioned not to place undue reliance on this information and should note that these measures as calculated by the Company, may differ materially from similarly titled measures reported by other companies. We believe that the presentation of Adjusted EBITDA and Adjusted EBITDA excluding Construction Service enhances an investor’s understanding of our performance and are useful for investors to assess our operating performance by excluding certain items that we believe are not representative of our core business. In addition, Adjusted EBITDA and Adjusted EBITDA excluding Construction Service are useful because they allow us to more effectively evaluate our operating performance and compare the results of our operations from period to period without regard to our financing methods, capital structure or income taxes and construction services (when applicable).

Net debt is calculated by deducting “Cash and cash equivalents” from total financial debt.

Figures ex-IAS 29 result from dividing nominal Argentine pesos for the Argentine Segment, by the average foreign exchange rate of the Argentine Peso against the US dollar in the period. Percentage variations ex-IAS 29 figures compare results as presented in the prior year quarter before IAS 29 came into effect, against ex-IAS 29 results for this quarter as described above. For comparison purposes, the impact of adopting IAS 29 in Aeropuertos Argentina 2000, the Company’s largest subsidiary in Argentina, is presented separately in each of the applicable sections of this earnings release, in a column denominated “IAS 29”. The impact from “Hyperinflation Accounting in Argentina” is described in more detail page 23 of this report.

Definitions and Concepts

Commercial Revenues: CAAP derives commercial revenue principally from fees resulting from warehouse usage (which includes cargo storage, stowage and warehouse services and related international cargo services), services and retail stores, duty free shops, car parking facilities, catering, hangar services, food and beverage services, retail stores, including royalties collected from retailers’ revenue, and rent of space, advertising, fuel, airport counters, VIP lounges and fees collected from other miscellaneous sources, such as telecommunications, car rentals and passenger services.

Construction Service revenue and cost: Investments related to improvements and upgrades to be performed in connection with concession agreements are treated under the intangible asset model established by IFRIC 12. As a result, all expenditures associated with investments required by the concession agreements are treated as revenue generating activities given that they ultimately provide future benefits, and subsequent improvements and upgrades made to the concession are recognized as intangible assets based on the principles of IFRIC 12. The revenue and expense are recognized as profit or loss when the expenditures are performed. The cost for such additions and improvements to concession assets is based on actual costs incurred by CAAP in the execution of the additions or improvements, considering the investment requirements in the concession agreements. Through bidding processes, the Company contracts third parties to carry out such construction or improvement services. The amount of revenues for these services is equal to the amount of costs incurred plus a reasonable margin, which is estimated at an average of 3.0% to 5.0%.

About Corporación América Airports

Corporación América Airports acquires, develops and operates airport concessions. Currently, the Company operates 52 airports in 6 countries across Latin America and Europe (Argentina, Brazil, Uruguay, Ecuador, Armenia and Italy). In 2024, Corporación América Airports served 79.0 million passengers, 2.7% (or 0.4% excluding Natal) below the 81.1 million passengers served in 2023, and 6.2% below the 84.2 million served in 2019. The Company is listed on the New York Stock Exchange where it trades under the ticker “CAAP”. For more information, visit http://investors.corporacionamericaairports.com

Forward Looking Statements

Statements relating to our future plans, projections, events or prospects are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “believes,” “continue,” “could,” “potential,” “remain,” “will,” “would” or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to: the Covid-19 impact, delays or unexpected casualties related to construction under our investment plan and master plans, our ability to generate or obtain the requisite capital to fully develop and operate our airports, general economic, political, demographic and business conditions in the geographic markets we serve, decreases in passenger traffic, changes in the fees we may charge under our concession agreements, inflation, depreciation and devaluation of the AR$, EUR, BRL, UYU or the AMD against the U.S. dollar, the early termination, revocation or failure to renew or extend any of our concession agreements, the right of the Argentine Government to buy out the AA2000 Concession Agreement, changes in our investment commitments or our ability to meet our obligations thereunder, existing and future governmental regulations, natural disaster-related losses which may not be fully insurable, terrorism in the international markets we serve, epidemics, pandemics and other public health crises and changes in interest rates or foreign exchange rates. The Company encourages you to review the ‘Cautionary Statement’ and the ‘Risk Factor’ sections of our annual report on Form 20-F for the year ended December 31, 2019 and any of CAAP’s other applicable filings with the Securities and Exchange Commission for additional information concerning factors that could cause those differences.

Investor Relations Contact

Patricio Iñaki Esnaola

Email: [email protected]

Phone: +5411 4899-6716

KEYWORDS: Europe Luxembourg United States North America New York

INDUSTRY KEYWORDS: Transportation Air Transport Travel

MEDIA:

Logo
Logo
Posted on

Allegion Named 2025 Gallup Exceptional Workplace Award Winner

Allegion Named 2025 Gallup Exceptional Workplace Award Winner

Honor recognizes Allegion’s ‘most engaged workplace culture’ for second consecutive year

DUBLIN–(BUSINESS WIRE)–Allegion plc (NYSE: ALLE), a leading global security products and solutions provider, has received the 2025 Gallup Exceptional Workplace Award (GEWA) for the second consecutive year. This award recognizes the most engaged workplace cultures in the world — organizations that achieve more by helping their employees focus on what they do best.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319198272/en/

Gallup Exceptional Workplace Award: 2025 Engagement + Strengths Winner

Gallup Exceptional Workplace Award: 2025 Engagement + Strengths Winner

Gallup found that Allegion, through an emphasis on and investment in strengths, continued to engage and develop its people in innovative ways, setting new benchmarks for workplace excellence.

“Congratulations to this year’s Gallup Exceptional Workplace Award winners for setting the standard for a thriving workplace. Your commitment to creating an environment where employees feel valued, heard and empowered to do their best work is truly remarkable. By prioritizing both people and performance, you are shaping the future of work and proving that exceptional workplaces drive real results,” said Jon Clifton, Gallup CEO.

“At Allegion, we believe a strengths-based culture of engagement is an integral part of our company’s foundation,” said Jen Hawes, Allegion senior vice president and chief human resources officer. “When employees are empowered to leverage their unique talents and feel truly connected to our mission, we create an environment where innovation thrives, collaboration deepens and everyone can do their best work.”

“Our team of highly engaged experts are a key differentiator for our company. They solve complex problems and deliver exceptional results for our customers,” added John H. Stone, Allegion president and CEO. “I’m proud of our people, our values and the commitments we hold to employee engagement and strengths development.”

Gallup’s meta-analysis on team engagement and performance is the most comprehensive workplace study ever conducted, with data on more than 3.3 million employees in 347 organizations across 53 industries and 90 countries. Highly engaged organizations significantly outperform their peers on important business outcomes, including customer ratings, profitability, productivity, turnover, safety incidents, shrinkage, absenteeism, quality, wellbeing and organizational citizenship.

For a complete list of GEWA winners, visit the 2025 Gallup Exceptional Workplace Award Winners page. Learn more about the awards here.

About Allegion

At Allegion (NYSE: ALLE), we design and manufacture innovative security and access solutions that help keep people safe where they live, learn, work and connect. We’re pioneering safety with our strong legacy of leading brands like CISA®, Interflex®, LCN®, Schlage®, SimonsVoss® and Von Duprin®. Our comprehensive portfolio of hardware, software and electronic solutions is sold around the world and spans residential and commercial locks, door closer and exit devices, steel doors and frames, access control and workforce productivity systems. Allegion had $3.8 billion in revenue in 2024. For more, visit www.allegion.com.

Media Contact:

Whitney Moorman – Director, Global Communications

317-810-3241

[email protected]

Analyst Contact:

Jobi Coyle – Director, Investor Relations

317-810-3107

[email protected]

Josh Pokrzywinski – Vice President, Investor Relations

463-210-8595

[email protected]

KEYWORDS: Europe Ireland United States North America Indiana

INDUSTRY KEYWORDS: Technology Communications Office Products Home Goods Retail Other Professional Services Finance Interior Design Architecture Professional Services Philanthropy Building Systems Security Fund Raising Foundation Other Manufacturing Residential Building & Real Estate Commercial Building & Real Estate Hardware Construction & Property Manufacturing Consumer Electronics Public Relations/Investor Relations

MEDIA:

Photo
Photo
Gallup Exceptional Workplace Award: 2025 Engagement + Strengths Winner
Logo
Logo
Posted on

Lineage, Inc. Declares Dividend for First Quarter 2025

Lineage, Inc. Declares Dividend for First Quarter 2025

NOVI, Mich.–(BUSINESS WIRE)–
Lineage, Inc. (NASDAQ: LINE) (the “Company”), the world’s largest global temperature-controlled warehouse REIT, today announced that its Board of Directors has declared a cash dividend of $0.5275 per share for the first quarter of 2025. The dividend will be paid on April 21, 2025, to shareholders of record of the Company’s common stock as of the close of business on March 31, 2025.

About Lineage

Lineage, Inc. (NASDAQ: LINE) is the world’s largest global temperature-controlled warehouse REIT with a network of over 485 strategically located facilities totaling approximately 86 million square feet and approximately 3.1 billion cubic feet of capacity across countries in North America, Europe, and Asia-Pacific. Coupling end-to-end supply chain solutions and technology, Lineage partners with some of the world’s largest food and beverage producers, retailers, and distributors to help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, feed the world. Learn more at onelineage.com and join us on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Lineage intends for all such forward-looking statements to be covered by the applicable safe harbor provisions for forward-looking statements contained in those acts. Such forward-looking statements can generally be identified by Lineage’s use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue,” “seek,” “objective,” “goal,” “strategy,” “plan,” “focus,” “priority,” “should,” “could,” “potential,” “possible,” “look forward,” “optimistic,” or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Such statements are subject to certain risks and uncertainties, including known and unknown risks, which could cause actual results to differ materially from those projected or anticipated. Therefore, such statements are not intended to be a guarantee of Lineage’s performance in future periods. Except as required by law, Lineage does not undertake any obligation to update or revise any forward-looking statements contained in this release.

Investor Relations Contact

Evan Barbosa

VP, Investor Relations

[email protected]

Media Contact

Megan Hendricksen

VP, Global Marketing & Communications

[email protected]

KEYWORDS: United States North America Michigan

INDUSTRY KEYWORDS: Supply Chain Management Retail Communications Construction & Property REIT Public Relations/Investor Relations

MEDIA:

Logo
Logo